WaveMan
WaveMan · Company
TKNO · Alpha Teknova, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TKNO Alpha Teknova (TKNO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0001850902
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
48
13F, latest reported quarter

Alpha Teknova insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Alpha Teknova, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Lowell Matthew
Chief Financial Officer
BUY
2026-03-09 SECtraded 2026-03-06
40,000
$87.6K
+175.6%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 12, 2024.
  • +57.6% median (+86.0% mean) 90-day return after 4 previous buys.
  • The trade is 23.8% of the 168,376 shares held after it.
  • 1 other insider bought within 30 days.
  • 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Lowell Matthew bought about $87.6K of TKNO on Mar 6, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 48 funds added in the latest 13F quarter.
Gunstream Stephen
President and CEO
BUY
2026-03-09 SECtraded 2026-03-06
26,000
$55.9K
+175.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jul 12, 2024.
  • +31.1% median (+63.4% mean) 90-day return after 6 previous buys.
  • The trade is 9.6% of the 269,497 shares held after it.
  • 1 other insider bought within 30 days.
  • 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Gunstream Stephen bought about $55.9K of TKNO on Mar 6, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 48 funds added in the latest 13F quarter.
DEMSKI MARTHA J
Director
SELL
2025-07-01 SECtraded 2025-06-27
8,000
$40.5K
+39.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 66.7% of the 12,000 shares held after it.
  • No other insider sold within 30 days.
  • 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEMSKI MARTHA J sold about $40.5K of TKNO on Jun 27, 2025, the largest insider sale at the company since 2023; 48 funds added in the latest 13F quarter.
Telegraph Hill Partners IV, L.P.
BUY
2024-07-16 SECtraded 2024-07-12
11,126,929
$13.8M
+270.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 11,126,929 shares held after it.
  • 2 other insiders bought within 30 days.
  • 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Telegraph Hill Partners IV, L.P. bought about $13.8M of TKNO on Jul 12, 2024, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 48 funds added in the latest 13F quarter.
Telegraph Hill Partners IV, L.P.
BUY
2024-07-16 SECtraded 2024-07-12
969,844
$1.2M
+270.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 969,844 shares held after it.
  • 2 other insiders bought within 30 days.
  • 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Telegraph Hill Partners IV, L.P. bought about $1.2M of TKNO on Jul 12, 2024; 2 other insiders bought within 30 days and 48 funds added in the latest 13F quarter.
39 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 34 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
48 funds bought in last quarter
below 54% of Pharma & Biotech
Revenue
+7.4% year over year
more than 56% of Pharma & Biotech
Margin
-42.6% net margin
more than 51% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
10.0% of the float short (float per yahoo 2026-10-27) · 5.8 days to cover · settled 2026-10-15
below 59% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TKNO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+23.4%12M
-65%-23%+20%+62%2025-102025-122026-022026-042026-062026-082026-10 2026-03-06 · Lowell Matthew bought $87.6K2026-03-06 · Gunstream Stephen bought $55.9K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TKNO: institutional holders (13F)

13F holdings, latest reported quarter
ROYCE & ASSOCIATES LP
1,661,395 sh
$9.4M
VANGUARD CAPITAL MANAGEMENT LLC
1,614,045 sh
$9.2M
Roubaix Capital, LLC
1,579,404 sh
$9.0M
BlackRock, Inc.
879,786 sh
$5.0M
UBS Group AG
631,967 sh
$3.6M

Congress trades in TKNO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TKNO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

TKNO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Royce Micro-Cap Fund
$2.7M position · as of 2026-06-30
0.6%
Royce Capital Fund - Micro-Cap Portfolio
$853.3K position · as of 2026-06-30
0.6%
Ultra-Small Company Market Fund
$426.0K position · as of 2026-06-30
0.3%
NVIT GS Small Cap Equity Insights Fund
$116.8K position · as of 2026-06-30
0.1%
Goldman Sachs Small Cap Growth Insights Fund
$126.8K position · as of 2026-07-31
0.0%
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund
$60.5K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 48 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TKNO financials

Revenue growth
+7.4%
XBRL, annual
Net margin
-42.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$43.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-38.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$7.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.21x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Cash flow to debt
-0.47x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Return on equity
-24.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-16.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-16.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$388.9M
market value at close 2026-10-27 on 2026-08-05 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
FCF yield
-1.9%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$40.5M$37.7M$36.7M$41.4M
Gross profit$13.4M$7.2M$10.3M$17.5M
Operating income-$17.0M-$26.1M-$35.6M-$49.7M
Net income-$17.3M-$26.7M-$36.8M-$47.5M
EPS (diluted)-0.32-0.57-1.16-1.69
Operating cash flow-$8.6M-$12.4M-$18.8M-$27.4M
Cash$5.9M$3.7M$28.5M$42.2M
Long-term debt$13.1M$9.4M$13.3M$22.0M
SEC XBRL, fiscal years, as known on 2026-10-28

TKNO Stock Sonar score 5/7 axes

Find similar shapesCompare

TKNO ranks highest on profitability (72nd percentile) and risk and compliance (69th), and lowest on institutional and government (46th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
72
Inputs
  • Return on equity-24.2% · 70 pct, sector of 545
  • Return on assets-16.3% · 70 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-16.4% · 76 pct, sector of 576
Financial health
52
Inputs
  • Debt to equity0.21x · 44 pct, sector of 352
  • Cash flow to debt-0.47x · 60 pct, sector of 371
Growth
56
Inputs
  • Revenue growth, YoY+7.4% · 56 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
46
Inputs
  • Funds adding, latest quarter48 · 46 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
69
Inputs
  • Short interest, % of float+10.0% · 40 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+1.1% · 98 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies